| Name | Title | Contact Details |
|---|
GlaxoSmithKline USA is a Philadelphia, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
EcoNugenics® was founded in 1995 by Dr. Isaac Eliaz, M.D., M.S., L.Ac. - a pioneer and expert in the field of integrative medicine, and a highly regarded clinical practitioner, formulator, researcher and author. Dr. Eliaz leads our research activities in natural, integrative approaches to cellular, immune, metabolic, digestive, and cardiovascular health, as well as detoxification.
Vitruvias is a specialty generic pharmaceutical business focused on the development and marketing of generic products with either (i) complex APIs that are difficult to source, or (ii) finished dosage forms that are inherently difficult to manufacture. The highly skilled team at Vitruvias has expertise in all aspects of the pharmaceutical industry, including product development, licensing, regulatory affairs, marketing, financial analysis, distribution, managed care, trade relations and sales.
APLUS INSTITUTE is a North York, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
TherOx, Inc. (TherOx) is a private, venture-financed medical device company based in Irvine, California, dedicated to elevating the standard of care for treatment of heart attack patients. A heart attack is caused when an artery in the heart becomes blocked. Current treatment of heart attack is to reestablish blood flow in the blocked artery as quickly as possible. Typically, this is done with a combination of medication and a percutaneous coronary intervention (PCI) which may include the placement of a (intracoronary) stent. PCI successfully restores blood flow, but damage to the patient’s heart remains. Blood flow in the microvasculature downstream from the blockage is compromised, and critical heart muscle tissue is damaged – or infarcted – due to oxygen deprivation brought on by the heart attack. The intent of SuperSaturated Oxygen (SSO2) Therapy from TherOx is to salvage damaged heart tissue by placing a high concentration of oxygen (~760 – 1,000 mmHg, or 5 – 7 times normal levels) into the patient’s blood plasma and delivering it directly to the area impacted by the heart attack. SSO2 Therapy serves as a complement to PCI and stenting. Immediately following the interventional procedure, proprietary technology from TherOx mixes a pre-specified concentration of “SuperOxygenated” saline solution with the patient’s blood to produce SuperOxygenated blood. The SuperOxygenated blood is then delivered through a catheter to the oxygen deficient tissue. Company research has confirmed in clinical studies that SuperSaturated Oxygen Therapy has the potential to reverse ischemia and may resuscitate tissue that may otherwise die. SSO2 Therapy circulates the patient`s own blood via the existing arterial access site used for the stenting procedure. Thus, no new access site is required. The TherOx DownStream System and DownStream Cartridge bear the CE Mark but are not available for commercial distribution in the EU at this time.